Skip to main content
SpringerLink
Log in

Cystic fibrosis

Cost of illness and considerations for the economic evaluation of potential therapies

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Cystic fibrosis (CF) is the most common life-shortening inherited disease of the Caucasian race, with a prevalence of around 1 in 2500 live births. Advances in the treatment and management of respiratory and pancreatic disorders have dramatically increased the life expectancy of patients with CF. This article presents an overview of cost-of-illness studies of CF, identifies deficits in the available health economic analyses of CF and discusses which specific factors are essential for the economic evaluation of potential therapies, based on a critical review of the health economic literature on two main therapeutic strategies.

Cost-of-illness studies of CF have predominantly been restricted to direct costs. According to the literature, direct costs amount to between $US6200–16 300 (1996 values) per patient per year. As most studies likely underestimated the actual costs (e.g. by disregarding provision of certain healthcare services), real healthcare costs tend to be at the upper end of the cost range. Healthcare costs depend on the patient’s age (for adults, costs are approximately twice as high as for children), the grade of severity (the cost relationship of severe to mild CF is between 4.5 and 7.1) and other factors. Lifetime direct costs of CF are estimated at $US200 000–300 000 (at 1996 values and a discount rate of 5%).

Home intravenous (IV) antibacterial therapy and recombinant human DNase (rhDNase; dornase alfa) treatment are the two main therapeutic strategies most often evaluated in health economic studies of CF. While home IV antibacterial therapy (compared with inpatient IV antibacterial therapy) is assumed to be cost saving, rhDNase treatment is a very cost-intensive therapy intended to efficiently achieve health improvements.

Health economic analyses of future CF therapeutic technologies should present explicit data regarding healthcare services provision, resource consumption and unit costs. Indirect costs and patient costs should be considered more often than they have to date, particularly when they are significantly influenced by novel CF technologies. The perspective of health economic studies should be stated explicitly and always include the societal perspective. More economic studies should be based on a controlled, and preferably randomised, design. The observation period must be long enough to identify long-term effects of interventions. A greater number of effectiveness studies should be performed to determine costs and outcomes of therapies applied under everyday life conditions for patients with CF. Finally, international comparison studies should identify the influence of different healthcare systems on the costs and outcomes of interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1–9

    PubMed  CAS  Google Scholar 

  2. Dodge JA, Morison S, Lewis PA, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968–95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997; 77: 493–6

    Article  PubMed  CAS  Google Scholar 

  3. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 1996; 143: 1007–17

    Article  PubMed  CAS  Google Scholar 

  4. Lewis PA, Morison S, Dodge JA, et al. Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee. Thorax 1999; 54: 420–2

    Article  PubMed  CAS  Google Scholar 

  5. Stutts MJ, Canessa CM, Olsen JC. CFTR as a CAMP-dependent regulator of sodium channels. Science 1995; 269: 847–50

    Article  PubMed  CAS  Google Scholar 

  6. Guggino WB. Cystic fibrosis: the salt controversy. Cell 1999; 96: 607–10

    Article  PubMed  CAS  Google Scholar 

  7. Smith JJ, Travis SM, Greenberg EP, et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229–36

    Article  PubMed  CAS  Google Scholar 

  8. Matsui H, Grubb BR, Tarran R. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell 1998; 95: 1005–15

    Article  PubMed  CAS  Google Scholar 

  9. Davis PB. The gender gap in cystic fibrosis survival. J Gend Specif Med 1999; 2: 47–51

    PubMed  CAS  Google Scholar 

  10. Kollberg H. Increasing survival of Swedish patients with CF. Acta Univ Carol Med Praha 1990; 36: 213–4

    PubMed  CAS  Google Scholar 

  11. Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21: 153–8

    Article  PubMed  CAS  Google Scholar 

  12. Elborn IS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000 [published erratum appears in Thorax 1992; 47: 139]. Thorax 1991; 46: 881–5

    Article  PubMed  CAS  Google Scholar 

  13. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45: 61–73

    Article  PubMed  CAS  Google Scholar 

  14. van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev 2000; (2): CDO01401

    Google Scholar 

  15. Rodgers HC, Knox AJ. Pharmacological treatment of the bio-chemical defect in cystic fibrosis airways. Fur Respir J 2001; 17: 1314–21

    Article  CAS  Google Scholar 

  16. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001; 17: 93–6

    Article  PubMed  CAS  Google Scholar 

  17. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330–5

    Article  PubMed  CAS  Google Scholar 

  18. Doting G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Fur Respir J 2000; 16: 749–67

    Article  Google Scholar 

  19. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administra-tion of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23–30

    Article  PubMed  CAS  Google Scholar 

  20. Frangolias DD, Mahenthiralingam E, Rae S, et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999; 160: 1572–7

    PubMed  CAS  Google Scholar 

  21. Talmaciu I, Varlotta L, Mortensen J, et al. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000; 30: 10–5

    Article  PubMed  CAS  Google Scholar 

  22. Wark PA, Gibson PG. Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment. Respirology 2001; 6: 1–7

    Article  PubMed  CAS  Google Scholar 

  23. Cobos N, Danes I, Gartner S, et al. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Fur J Pediatr 2000; 159: 176–81

    CAS  Google Scholar 

  24. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187–91

    Article  PubMed  CAS  Google Scholar 

  25. De Meester J, Smits JM, Persijn GG, et al. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001; 20: 518–24

    Article  PubMed  Google Scholar 

  26. Granton IT, Kesten S. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Chest 1998; 113: 1013–8

    Article  PubMed  CAS  Google Scholar 

  27. Pauly MV. The economics of cystic fibrosis. In: Lloyd-Still JD, editor. Textbook of cystic fibrosis. Boston: John Wright PSG Inc., 1983: 465–76

    Google Scholar 

  28. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992; 47: 684–9

    Article  PubMed  CAS  Google Scholar 

  29. US Congress Office of Technology Assessment. Cystic fibrosis and DNA tests: implications of carrier screening. Washington: US Government Printing Office, 1992

  30. Wildhagen MF, Verheij JB, Verzijl JG, et al. Cost of care of patients with cystic fibrosis in the Netherlands in 1990-1 [published erratum appears in Thorax 1997; 52: 204]. Thorax 1996; 51: 298–301

    Article  PubMed  CAS  Google Scholar 

  31. Johnson JA, Connolly M, Jacobs P, et al. Cost of care for individuals with cystic fibrosis in Alberta: a regression approach to determining important cost drivers [working paper]. Edmonton (AB): Institute of Health Economics, 1996: 99–2

    Google Scholar 

  32. Ireys HT, Anderson GF, Shaffer TJ, et al. Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid Program, fiscal year 1993. Pediatrics 1997; 100:197–204

    Article  PubMed  CAS  Google Scholar 

  33. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999; 19: 1159–66

    Article  PubMed  CAS  Google Scholar 

  34. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999; 103: e72

    Article  PubMed  CAS  Google Scholar 

  35. Wildhagen MF, Verheij JB, Verzijl JG, et al. The nonhospital costs of care of patients with CF in the Netherlands: results of a questionnaire. Fur Respir J 1996; 9: 2215–9

    Article  CAS  Google Scholar 

  36. Ginsberg G, Blau H, Kerem E, et al. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Econ 1994; 3: 5–23

    Article  PubMed  CAS  Google Scholar 

  37. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Costeffectiveness in health and medicine. New York: Oxford University Press, 1996, 46

    Google Scholar 

  38. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for the economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997

  39. Bosso JA, Stephenson SE, Herbst JJ. Feasibility and cost savings of intravenous administration of amino-glycosides in outpatients with cystic fibrosis. Drug Intell Clin Pharm 1985; 19: 52–4

    PubMed  CAS  Google Scholar 

  40. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. J Pediatr 1987; 111: 28–33

    Article  PubMed  CAS  Google Scholar 

  41. Gilbert J, Robinson T, Littlewood JM. Home intravenous antibiotic treatment in cystic fibrosis. Arch Dis Child 1988; 63: 512–7

    Article  PubMed  CAS  Google Scholar 

  42. Kane RE, Jennison K, Wood C, et al. Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 1988; 4: 84–9

    Article  PubMed  CAS  Google Scholar 

  43. Strandvik B, Hjelte L, Malmborg AS, et al. Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatr 1992, 4

    Google Scholar 

  44. Bakker W, Vinks AA, Mouton JW, et al. Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibro sis; a multicenter study. Ned Tijdschr Geneeskd 1993; 137: 2486–91

    PubMed  CAS  Google Scholar 

  45. van Aalderen WMC, Mannes GPM, van Bommel G, et al. Continuous home intravenous antibiotic treatment of respiratory infections in 11 cystic fibrosis patients in the north of the Netherlands [in Dutch]. Ned Tijdschr Geneeskd 1993; 137: 2482–6

    PubMed  Google Scholar 

  46. Pond MN, Newport M, Joanes D, et al. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Fur Respir J 1994; 7: 1640–4

    Article  CAS  Google Scholar 

  47. Bramwell EC, Halpin DM, Duncan SF, et al. Home treatment of patients with cystic fibrosis using the ‘Intermate’: the first year’s experience. J Adv Nurs 1995; 22: 1063–7

    Article  PubMed  CAS  Google Scholar 

  48. van Aalderen WMC, Mannes GPM, Bosma ES, et al. Home care in cystic fibrosis patients. Fur Respir J 1995; 8: 172–5

    Article  Google Scholar 

  49. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997; 24: 42–7

    Article  PubMed  CAS  Google Scholar 

  50. Wolter JM, Bowler SD, Nolan PJ, et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Fur Respir J 1997; 10: 896–900

    CAS  Google Scholar 

  51. Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54: 358–60

    PubMed  CAS  Google Scholar 

  52. Winter RJD, George RJD, Deacock SJ, et al. Self administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis. Lancet 1984; 1: 1338–9

    Article  PubMed  CAS  Google Scholar 

  53. David TJ. Potential practical and legal problems with home administration of intravenous antibiotics for children with cystic fibrosis. In: David TJ, editor. Cystic fibrosis in children. Practical and legal aspects of intravenous antibiotic administration in the home. Amsterdam: Excerpta Medica (Glaxo), 1986: 3–14

    Google Scholar 

  54. Kuzemko JA, Williams KJ, Bigley J. Home intravenous treatment of pulmonary infections in cystic fibrosis. In: David TJ, editor. Cystic fibrosis in children. Practical and legal aspects of intravenous antibiotic administration in the home. Amsterdam: Excerpta Medica (Glaxo), 1986: 29–37

    Google Scholar 

  55. Graf von der Schulenburg JM, Greiner W, Klettke U, et al. Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment [in German]. Med Klin 1997; 92: 626–9

    Article  CAS  Google Scholar 

  56. Krauth C, Busse R, Smaczny C, et al. Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients: results of a controlled prospective study [in German]. Med Klin 1999; 94: 541–8

    Article  CAS  Google Scholar 

  57. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997; 11 (5): 385–8

    Article  PubMed  CAS  Google Scholar 

  58. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs measurement through quality of life?. A response to the recommendations of the Washington Panel. Health Econ 1997; 6: 253–9

    Article  PubMed  CAS  Google Scholar 

  59. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6: 511–4

    Article  PubMed  CAS  Google Scholar 

  60. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253–8

    Article  PubMed  CAS  Google Scholar 

  61. Rich D. Physicians, pharmacists and home infusion antibiotic therapy. Am J Med 1994; 97: 3–8

    Article  PubMed  CAS  Google Scholar 

  62. David TJ. Intravenous antibiotics at home in children with cystic fibrosis. J R Soc Med 1989; 82: 130–1

    PubMed  CAS  Google Scholar 

  63. Ellis JM. Let parents give the care: IV therapy at home in cystic fibrosis. Professional Nurse 1989; 4: 589–92

    Google Scholar 

  64. Sheldon P, Bender M. High-technology in home care. An overview of intravenous therapy. Nurs Clin North Am 1994; 3: 507–19

    Google Scholar 

  65. Stiver HG, Trosky SK, Cote DD, et al. Self-administration of intravenous antibiotics: an efficient, cost-effective home care program. CMAJ 1982; 127: 207–11

    CAS  Google Scholar 

  66. Hammond LJ, Caldwell S, Campbell PW. Cystic fibrosis, intravenous antibiotics, and home therapy. J Pediatr Health Care 1991; 5: 24–30

    Article  PubMed  CAS  Google Scholar 

  67. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. Drug Therapy 1996; 335: 179–88

    CAS  Google Scholar 

  68. Davies J, Trindade MT, Wallis C, et al. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23: 243–8

    Article  PubMed  CAS  Google Scholar 

  69. Fuchs III, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637–42

    Article  PubMed  CAS  Google Scholar 

  70. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of Domase Alfa in patients with advanced cystic fibrosis. Chest 1996; 110: 889–95

    Article  PubMed  CAS  Google Scholar 

  71. Milla CE. Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998; 53: 1014–7

    Article  PubMed  CAS  Google Scholar 

  72. Ranasinaha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199–202

    Article  Google Scholar 

  73. Shah PL, Scott SF, Geddes DM, et al. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995; 89: 499–502

    Article  PubMed  CAS  Google Scholar 

  74. Wilmott RW, Amin RS, Colin AA, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153: 1914–7

    PubMed  CAS  Google Scholar 

  75. Oster G, Huse DM, Lacey MJ, et al. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother 1995; 29: 459–64

    PubMed  CAS  Google Scholar 

  76. Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996; 12: 52–61

    Article  PubMed  CAS  Google Scholar 

  77. Brown TER, Glennie JL, Carleton BC. A pharmacoeconomic evaluation of DNase use in cystic fibrosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1996

    Google Scholar 

  78. Ledson MJ, Wahbi Z, Convery RP, et al. Targeting of domase alpha therapy in adult cystic fibrosis. J R Soc Med 1991; 7: 360–4

    Google Scholar 

  79. Marra CA, Carleton BC, Basmadjian D, et al. Cost of rhDNase in cystic fibrosis. Ann Pharmacother 1995; 29: 1050–1

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Epidemiology, Social Medicine and Health System Research, Hannover Medical School, 30623, Hannover, Germany

    Christian Krauth & Noushin Jalilvand

  2. University Hospital for Cardiology, Angiology and Pulmology, University of Magdeburg, Magdeburg, Germany

    Tobias Welte

  3. Department of Health Care Management, Technical University Berlin, Berlin, Germany

    Reinhard Busse

Authors
  1. Christian Krauth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noushin Jalilvand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reinhard Busse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Krauth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krauth, C., Jalilvand, N., Welte, T. et al. Cystic fibrosis. Pharmacoeconomic 21, 1001–1024 (2003). https://doi.org/10.2165/00019053-200321140-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321140-00002

Keywords

Search

Navigation